

1 **Vaccine-induced correlate of protection against fatal COVID-19 in the old and frail**
2 **during waves of neutralization resistant variants of concern.**

3
4 Linnea Vikström, M.S*., Peter Fjällström, M.S*., Yong-Dae Gwon, Ph.D., Daniel J. Sheward,
5 Ph.D., Julia Wigren-Byström, M.S., Magnus Evander, Ph.D., Oscar Bladh, M.D. Ph.D.,
6 Michael Widerström, M.D. Ph.D., Christian Molnar, M.D., Gunlög Rasmussen, M.D. Ph.D.,
7 Louise Bennet, M.D. Ph.D., Mikael Åberg, Ph.D., Jonas Björk, Ph.D., Staffan Tevell, M.D.
8 Ph.D., Charlotte Thålin, M.D. Ph.D., Kim Blom, Ph.D., Jonas Klingström, Ph.D., Benjamin
9 Murrell, Ph.D., Clas Ahlm, M.D. Ph.D., Johan Normark, M.D. Ph.D., Anders F Johansson,
10 M.D. PhD.#., Mattias NE Forsell, PhD.#

11

12 Correspondence to: Mattias.forsell@umu.se and anders.f.johansson@umu.se

13 * LV and PF contributed equally to the manuscript.

14 # AFJ and MNEF contributed equally to the manuscript.

15

16 **Author affiliations:** From the Department of Clinical Microbiology, Umeå University,
17 Sweden (LV, PF, YDG, JWB, ME, MW, CA, JN, AFJ and MNEF), The Department of
18 Microbiology, Tumor and Cell Biology, Karolinska Institutet, Sweden (DS and BM), The
19 Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm,
20 Sweden (OB and CT), Familjeläkarna Stockholm, Sweden (CM), School of Medical Sciences,
21 Örebro University (GR), Clinical Studies Sweden, Forum South, Skåne University Hospital
22 and Department of Clinical Sciences, Lund University, Sweden (LB), The Department of
23 Medical Sciences, Clinical Chemistry and SciLifeLab, Uppsala University, Uppsala, Sweden
24 (MÅ), The Division of Occupational and Environmental Medicine, Lund University, Lund,
25 Sweden (JB). The Department of Infectious Diseases, Karlstad Hospital and Centre for
26 Clinical Research and Education, Region Värmland and Faculty of Medicine and Health,
27 Örebro University, Örebro, Sweden (ST), The Swedish Public Health Agency, Stockholm,
28 Sweden (KB) and The Department of Biomedical Clinical Sciences, Linköpings University,

29 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**
Sweden (JK)

30 **ABSTRACT**

31 **Background:** To inform future preventive measures including repeated vaccinations, we have
32 searched for a clinically useful immune correlate of protection against fatal Covid-19 among
33 nursing homes residents. **Methods:** We performed repeated capillary blood sampling with
34 analysis of S-binding IgG in an open cohort study with inclusion of nursing home residents in
35 Sweden. We analyzed immunological and registry data collected from September 2021 with
36 end of follow-up 31 August 2022. The study period included implementation of the 3rd and 4th
37 mRNA monovalent vaccine doses and Omicron virus waves. **Findings:** A total of 3012 nursing
38 home residents with median age 86 were enrolled. The 3rd mRNA dose elicited a 99-fold
39 relative increase of S-binding IgG among 2606 blood-sampled individuals and corresponding
40 increase of neutralizing antibodies. The 4th mRNA vaccine dose boosted the levels 3.8-fold.
41 Half-life of S-binding IgG was 72 days. A total 528 residents acquired their first SARS-CoV-2
42 infection after the 3rd or the 4th vaccine dose and the 30-day mortality was 9.1%. We found no
43 indication that levels of vaccine-induced antibodies protected against infection with Omicron
44 VOCs. In contrast, the risk of death was inversely correlated to levels of S-directed IgG below
45 the 20th percentile. The risk plateaued at population average above lower 35th percentile of S-
46 binding IgG. **Interpretation:** In the absence of neutralizing antibodies that protection from
47 infection, quantification of S-binding IgG post vaccination may be useful to identify the most
48 vulnerable for fatal Covid-19 among the oldest and frailest. This information is of importance
49 for future strategies to protect vulnerable populations against neutralization resistant variants of
50 concern. **Funding:** Swedish Research Council, SciLife, Knut and Alice Wallenberg Foundation
51 and Vinnova.

52

53 INTRODUCTION

54 Prior to the rollout of SARS-CoV-2 vaccines, Covid-19 caused substantial morbidity and
55 mortality worldwide, particularly in older individuals. In Sweden, elderly care services are
56 provided in nursing homes staffed and equipped to maintain good quality of life ¹⁻³.
57 Approximately 80% of the individuals in this population are over the age of 80 and many have
58 comorbidities including dementia^{4,5}. Early in the pandemic, diagnosed SARS-CoV-2 infection
59 was associated with a 40% excess 30-day mortality among residents at Swedish nursing homes⁵.
60 Accordingly, nursing home residents were prioritized for vaccination against Covid-19, and
61 88% had received two vaccine doses as of 1 April 2021⁶. A majority of these individuals
62 received two doses of BNT162b2 (Pfizer/BioNTech) as their primary vaccination regimen.

63

64 A two-dose SARS-CoV-2 mRNA vaccine regimen induces SARS-CoV-2 Spike-directed
65 antibody-responses in elderly individuals ⁷⁻¹¹, though advanced age has been associated with
66 weaker and less durable responses ^{8,12,13}. Low titer antibody responses may be even more
67 vulnerable to antibody escape by emerging variants of concern¹⁴, raising concerns about the
68 longevity of protection against infection and disease among older nursing home residents. To
69 counteract the waning of specific immune responses, repeated vaccinations have been
70 administered at Swedish nursing homes. A third dose was administered to residents at nursing
71 homes approximately eight months after the primary two-dose regimen. A fourth dose was then
72 recommended to individuals >80-year-old and to all nursing home residents approximately five
73 months after the third dose. For both the third and fourth doses, the vaccine regimens comprised
74 of either BNT162b2 or a half-dose of mRNA-1273 (Moderna). The beneficial effect of these
75 booster doses in reducing infections and mortality in the general population in Sweden has
76 previously been demonstrated¹⁵.

77

78 A measurable correlate of protection against Covid-19 mortality would be extremely valuable
79 to identify individuals and cohorts at risk for severe or fatal outcome after a SARS-CoV-2
80 infection. The aim of the study was to evaluate if levels of vaccine-induced circulating IgG
81 could predict susceptibility for infection or future fatal Covid-19 from infection with variants
82 of concern among nursing home residents. Thus, in a cohort of nursing home residents, we
83 characterized longitudinal Spike (S) -binding antibody responses with high resolution after
84 three or four vaccine-doses and then correlated the results with registry-based data on infections
85 and mortality on an individual basis.

86

87 **RESULTS**

88

89 **Population and setting**

90 A total of 3012 nursing home residents from 114 nursing homes were enrolled in an
91 observational open cohort study in Sweden. The inclusion period was from 16 September 2021
92 to 13 April 2022, with inclusion start before the roll-out of a third Covid-19 vaccine dose with
93 a mRNA vaccine. Characteristics of the population at baseline, vaccinations, and capillary
94 sampling for repeated analyses of SARS-CoV-2 antibodies in blood are described in Table 1.
95 Both metropolitan and less densely populated regions were represented (Figure 1A), and the
96 residents comprised a higher proportion of women than men above 75 years (Figure 1B). A
97 high weekly incidence within the cohort of PCR-verified SARS-CoV-2 infections with
98 Omicron variants of concern (VOC) facilitated analyses of outcomes with relation to immune
99 responses (Figure 1C). After the laboratory analyses, at least one S-binding IgG observation in
100 blood was available for 2607 study subjects and there were a total number of 6958 S-binding
101 IgG observations within the cohort.

102

103 **Table 1. Characteristics of the study population.**

Characteristic	All regions (N=3012)	Northern and central regions (N=2174)	Metropolitan regions (N=838)
Median age (range) -yr	86 (41 - 105)	86 (41 - 105)	85 (59 - 103)
Female sex -no. (%)	1865 (64.1)	1374 (63.2)	547 (65.3)
History of PCR-verified SARS-CoV-2 at inclusion -no. (%)	405 (13.4)	196 (9.0)	209 (24.9)
History of vaccination at inclusion -no. (%) *			
1 dose	39 (1.3)	28 (1.3)	11 (1.3)
2 doses	1829 (60.7)	1756 (80.8)	73 (8.7)
3 doses	1144 (38.0)	390 (17.9)	754 (90.0)
Interval between vaccine doses -days *			
Dose 1 - 2 median (range)	28 (14 - 477)	28 (14 - 477)	21 (17 - 416)
Dose 2 - 3 median (range)	245 (57 - 555)	242 (100 - 555)	252 (57 - 532)
Dose 3 - 4 median (range)	146 (69 - 353)	143 (69 - 350)	149 (82 - 353)
Median inclusion date	08 Oct 2021	05 Oct 2021	22 Nov 2021
Subjects entering/leaving study -no.			
16 Sept - 27 Nov 2021	2563 / 160	2047 / 146	516 / 14
28 Nov 2021 - 27 Feb 2022	193 / 265	71 / 201	122 / 64
28 Feb - 13 April 2022	256 / 103	56 / 81	200 / 22
Subjects donating blood sample -no.			
Sampling period 1: 28 Sept - 27 Nov 2021	1570	1570	0
Sampling period 2: 28 Nov 2021 - 19 Jan 2022	1950	1474	476
Sampling period 3: 28 Feb - 05 May 2022	1791	1258	533
Sampling period 4: 19 May - 23 July 2022	1647	1218	429
No. of blood samples donated per person -no.			
One	496	331	165
Two	654	460	194
Three	798	503	295
Four	690	690	0

104 * 51 study subjects received ChAdOx1 (Astra-Zeneca) as 1st and/or 2nd dose.

105 **Robust induction of S-directed IgG after a third and fourth dose of mRNA vaccination**
106 **among nursing home residents**

107

108 The vaccine coverage was 95.9% for the third dose and 80.1% for the fourth dose. We found
109 that >90% of the vaccinees received the third dose within 41 calendar days (median date
110 October 13, 2021), and >90% received the fourth dose within 37 calendar days (median date
111 March 7, 2022). We analyzed S-binding IgG levels before and after the third mRNA vaccination
112 dose with either the standard dose of BNT162b2 or a half-dose mRNA-1273 given after a
113 primary 2-dose regimen of vaccination with BNT162b2 eight months before (Figure 2A).
114 Previously infected individuals had higher anti-S levels both before and after vaccination.
115 Infection-naïve individuals displayed a 99-fold relative increase in anti-S IgG levels (median
116 AUC 352 at day-40 to -1 before dose 3 (N=653); median AUC 34,978 at day 14 to day 28 after
117 dose 3 (N=185)). By logarithmic linear regression, we estimated a mean anti-S IgG level decline
118 between day 20 and 80 post dose 3 at 1.3% per calendar day, equivalent to a half-life of 70.2
119 days. The increase in S-binding IgG after dose 3 was reflected in an increased capacity of serum
120 antibodies to outcompete ACE-2 binding to the Wu-1 S-protein *in vitro* (Supplemental Figure
121 1A).

122

123 By investigating capillary blood samples taken approximately 1 month after the third dose, we
124 found no difference in S-binding levels between previously uninfected nursing home residents
125 and previously uninfected community living individuals up to the age of 65. (Figure 2B,
126 supplemental table 1). For both groups, the levels of S-binding IgG were significantly lower
127 when compared to individuals with a confirmed SARS-CoV-2 infection prior to the third dose.

128

129 In comparison with the third dose, the fourth dose led to a more modest 3.8-fold relative
130 increase in circulating S-binding IgG (median AUC 14,587 from day -40 to -1 before dose 4
131 (N=364); median AUC = 55,729 from day 14 to 28 post dose 4 (N=701)) (Figure 2C), again
132 reflected by an increased capacity of serum antibodies to outcompete ACE-2 binding to the
133 Wu-1 S-protein (Supplemental Figure 1B). There was no significant difference in the decline
134 of S-binding IgG after 4th vaccine dose as compared with after the third vaccine dose (p-value
135 0.579).

136

137 By generalized additive modelling, we found that median AUC of S-binding IgG after the third
138 mRNA vaccine dose was 1.75 times higher with a half dose mRNA-1273 (N=202) than with
139 BNT162b2 (N=1576) (p-value <0.0001) (Supplemental figure 2). The modelling revealed no
140 significant gender difference in the response levels (p=0.525). Given the lack of a formal
141 randomization between the vaccine brands in the study design and that our goal was to study
142 overall vaccine responses in the nursing home population, we did not deem that further
143 stratification of data based on vaccine-moiety given was warranted.

144

145 **Comparative analysis of vaccine-induced S-specific antibodies after a 4th dose between old** 146 **and young**

147 Venous blood sampling allowed us to do a more detailed serum analysis on days 0, 7-10 and
148 30 after the fourth vaccine dose. We focused on SARS-CoV-2 unexposed individuals and found
149 that the fourth dose had induced similar increases in S-binding IgG in serum from old persons
150 at nursing homes (median AUC_{pre4} 12398 to AUC_{post4} 66359), community living persons aged
151 >66 (median AUC_{pre4} 20885 to AUC_{post4} 77142) or community living persons up to the age of
152 65 (median AUC_{pre4} 10843 to AUC_{post4} 67741) (Figure 3A, supplemental table 2). This was
153 reflected by significantly increased *in vitro* neutralizing titers against the original SARS-CoV-

154 2 strain among old persons at nursing homes, community living persons over the age of 65 or
155 up to the age of 65 (5.3x, 3.7x or 6.2x increase, respectively) (Figure 3B). Statistical analysis
156 demonstrated that samples from 5 individuals under the age of 65 had slightly higher median
157 neutralization titer than samples from 16 nursing home residents after a fourth dose, whereas
158 27 community-living old individuals had higher neutralization titers than the nursing home
159 residents prior to the fourth dose. We could also demonstrate that the increase in homologous
160 neutralization was associated with enhanced neutralization of Omicron (BA.2, BA.2.75 and
161 BA.5) by serum from nursing home residents (Figure 3C).

162

163 **Infection with relation to booster doses at nursing homes**

164 After study start 16 September 2021, 25% of included study subjects (765/3012) acquired a
165 primary PCR verified SARS-CoV-2-infection. Twenty-seven study subjects acquired a second
166 PCR verified infection. None was registered with three or more PCR-verified infections during
167 the pandemic. Thirty-two subjects acquired the primary PCR verified infection during the delta
168 virus dominance from 16 September 2021 to 31 December 2021 and 733 acquired the primary
169 infection during the remainder of the study, where Omicron variants BA.1 and BA.2 were
170 dominant until superseded by BA.5 in June 2022.

171

172 We determined if vaccine-induced antibody levels had an impact on susceptibility to BA.1 or
173 BA.2 infection by comparing projected antibody levels among study subjects that acquired
174 PCR-verified infection with the levels among study subjects not acquiring infection. Among
175 528 previously infection-naïve study subjects vaccinated with three mRNA doses, we found no
176 difference in levels of S-specific IgG to study subjects that subsequently acquired infection over
177 the corresponding 14-day periods after the third mRNA vaccine dose (Supplemental figure 3).

178

179 **Antibody levels in relation to mortality at nursing homes**

180 Throughout the study period, 781 study subjects died: 243 from 16 September to 31 December
181 2021, and 538 from 1 January to 31 August 2022. A main reason for that some study subjects
182 did not donate a blood sample after inclusion was short life expectancy: median time to death
183 for 2607 subjects donating or 405 subjects not donating blood were 149 and 37.5 days after
184 inclusion, respectively. From study start until the end of register follow-up 30 September 2022,
185 65 deaths occurred within 30 days after a PCR-verified SARS-CoV-2 infection, five during
186 Delta and 60 during the Omicron waves.

187
188 Among the 528 individuals that acquired their first SARS-CoV-2 infection after the third or the
189 fourth vaccine dose and where we had an appropriately timed analysis of S-directed IgG
190 available, the 30-day mortality was 9.1% (48 deaths/528 cases). This compared with a non-
191 covid-related 30-day mortality of 2.6% (27/1056) among control individuals sampled at the
192 same day (Figure 4A). We found no difference in 30-day mortality between individuals that
193 acquired infection after the third (32 deaths/362 cases) or the fourth mRNA vaccine dose (16
194 deaths/166 cases) (Kaplan-Meier logrank test, $p=0.75$) (Supplemental figure 4)

195
196 The 30-day mortality risk was higher among the 528 previously SARS-CoV-2 infection naïve
197 individuals with low levels of S-directed IgG and this effect plateaued to reach the population
198 average at approximately the 35th percentile (Figure 4B). Sensitivity analyses using stepwise
199 Kaplan-Meier curves showed that an increased 30-day mortality effect was significant below
200 to the 20th percentile of circulatory S-binding IgG (Supplemental figure 5). For example,
201 individuals with the 10th percentile lowest S-binding IgG (N=53) had projected AUCs at <479
202 at day 60 post the 3rd mRNA vaccine dose and 24.5% (13/53) 30-day mortality after PCR-
203 verified SARS-CoV-2 infection. This contrasted with 7.4% (35/475) mortality among

204 individuals with a measured AUC ≥ 479 (N=475). We further modelled 30-day mortality using
205 Cox proportional hazards regression to take additional risk factors for fatal SARS-CoV-2 into
206 account. By this analysis, we found that nursing home residents with an AUC < 479 were at
207 increased risk (hazard ratio 3.61, p-value < 0.0001), as were residents infected with SARS-CoV-
208 2 (hazard ratio 2.70, p-value < 0.0001) or those of male gender (hazard ratio 2.19, p-value
209 0.0086). Finally, and as well established, we found that each one-year increase in age increased
210 the risk for Covid-19-related mortality (hazard ratio 1.04, p-value 0.0216) (Supplemental table
211 3). We found no significant interaction effect between an AUC < 479 and increased risk to
212 acquire a SARS-CoV-2 infection (p-value 0.1219). Taken together, the Cox modelling suggests
213 that on top of an increased mortality imposed by SARS-CoV-2 infection there is an overall
214 increased 30-day mortality among individuals with low S-antibody responses.

215

216 **DISCUSSION**

217

218 A nationally coherent vaccination scheme and a strong clinical staff network at nursing homes
219 and a proven strategy to collect capillary blood samples¹⁶ allowed us to prospectively analyze
220 vaccine-induced humoral immunity and to combine these data with high-quality register data
221 on the individual level. The nursing home population in Sweden was continuously surveilled
222 by rigorous PCR-based diagnostics of suspected SARS-CoV-2 infections during the study, in
223 accordance with national and regional recommendations. This facilitated meaningful follow-up
224 of 30-day mortality from SARS-CoV-2 infection and a comparison with vaccine-induced
225 antibody responses.

226

227 By a detailed analysis of immune responses, we verified an increase in cross-neutralizing
228 antibodies against Omicron lineages BA.1, BA.2.75, and BA.5 after the fourth dose of mRNA

229 vaccination. This is consistent with increased antibody-mediated neutralization of the
230 homologous original SARS-CoV-2 strain to increase protection also against in vitro infection
231 with VOCs^{14,17}. The relatively lower boost effect of the 4th vaccination, as compared with the
232 3rd may be explained, at least in part, by a previously described feedback mechanism where
233 pre-existing specific antibodies can limit re-activation of humoral immunity¹⁸⁻²⁰. Our analysis
234 demonstrated that both the 3rd and the 4th vaccine dose induced a boost effect on SARS-CoV-2
235 S-binding that was similar between the study cohort and comparator groups of community
236 living individuals. We also found that the 4th vaccine dose induced significantly higher
237 neutralizing antibody titers in sera from five younger community living individuals than in sera
238 from nursing home residents, but not from community living individuals over the age of 65.
239 These data support that age related variability of the immune response to two doses of mRNA
240 vaccination had remained even after additional booster doses^{8,12}

241
242 The study period included the first omicron waves in Sweden and started at a time point when
243 the third mRNA vaccination was distributed to nursing home residents. We found no pattern
244 supporting that higher levels of circulating S-binding IgG protected against SARS-CoV-2
245 infection. This may be attributable to the described significant escape from neutralizing
246 antibodies by Omicron^{21,22}. It has previously been shown that vaccine-induced neutralizing
247 antibodies provided a correlate of protection against infection with the ancestral strain or
248 relatively homologous VoCs^{23,24}. Our results complement these data and demonstrates that S-
249 binding IgG antibody levels provide a correlate of protection against fatality related to
250 infections with VoCs.

251
252 Importantly, our analyses identify a threshold titer of anti-S IgG in capillary blood taken after
253 the 3rd vaccine dose below which there was significantly increased risk of fatal Covid-19. We

254 found that the study subjects having the 20th lowest percentile of S-binding IgG 60 days after
255 the 3rd vaccine dose had a significantly increased risk of fatal Covid-19. The risk effect included
256 study subjects that in addition to the 3rd vaccine dose also received the 4th dose. We conclude
257 that S-specific IgG against the original SARS-CoV-2 strain can serve as a correlate of protection
258 against fatal Covid-19 after infection with SARS-CoV-2 variants that demonstrate significant
259 immune escape from neutralizing antibodies. An additional interesting observation was that
260 Covid-19-related fatalities occurred within 20 days of a confirmed SARS-CoV-2 infection in
261 all individuals with low S-specific IgG in blood. This could indicate a role of non-neutralizing
262 antibodies to control the infection, as previously suggested²⁵. Importantly, individuals with low
263 S-specific IgG in circulation represented a minority, and our data demonstrate that between 70-
264 80% of all individuals at Swedish nursing homes have achieved maximal vaccine-induced
265 protection against fatal Covid-19 after 3 or 4 doses of monovalent mRNA vaccination.

266

267 The study has certain limitations; Nursing home residents at a terminal stage of life were not
268 included in the study, we lacked detailed information comorbidities and data to describe
269 severity of infection was not accessible. Hence, this study was limited to an understanding of
270 diagnosed SARS-CoV-2 infections and 30-day mortality. Moreover, we could not perform
271 neutralization assays on the small sample volumes acquired from capillary blood, and we lacked
272 information on mucosal Spike-specific IgA levels that may be importance to for protection
273 against infection ^{26,27}. These limitations highlight the need for further studies to address these
274 issues and provide a more comprehensive understanding of the impact of vaccination and
275 correlates of protection against SARS-CoV-2 variants of concern.

276

277 In conclusion, the data presented here demonstrate that levels of vaccine-induced antibodies in
278 capillary blood can act as a correlate of protection against fatal Covid-19 among elderly at

279 nursing homes after infection with neutralization resistant VOCs. Together with information of
280 S-specific antibody-decline, these data may be used to predict the long term overall protective
281 effect after vaccination and provide information for the implementation of future strategies to
282 protect high-risk groups against VOC-related mortality.

283

284 **MATERIALS AND METHODS**

285

286 **Study design and population**

287 Study subjects living in nursing homes were included if they had received at least one Covid-
288 19 vaccine dose and volunteered to participate in donating capillary blood for immunological
289 analyses and linking with registry data. Informed consent was obtained via an oral and written
290 procedure either the individual or their legal representative (usually next-of-kin) at the nursing
291 home. We used a prospective open cohort design where study subjects could choose to be
292 included every third month, or if already included, continue to donate a capillary blood sample.
293 To enable comparison of immunological responses in nursing home residents, we included
294 community living study subjects under and over the age of 65. Consent procedures, ethical
295 permits and more details on design and population is found in Supplemental methods section.

296

297 **Data sources, and linkage**

298 Immunological data from individuals were linked with data in the National vaccine-register
299 (Swedish Public Health Agency), the register containing mandatory reports of all SARS-CoV-
300 2 laboratory and clinical diagnoses in Sweden (SmiNet, Swedish Public Health Agency), and
301 vital status in the total population register (The Swedish Tax Agency) using the person identity
302 number given to all persons registered in Sweden.

303

304 **Sampling strategies**

305 The capillary sampling strategy utilized has been previously described¹⁶, with few
306 modifications. Briefly, individual capillary blood sampling kits were sent to study participants
307 via postal services and sampling was conducted by finger pricking by the individual study
308 subject or assisted by an employee at the nursing home.

309

310 **S-binding antibody responses, N-binding and ACE-competition**

311 Circulating IgG against vaccine-derived S proteins were measured in serum or eluted capillary
312 blood as previously described²⁸. Binding antibodies to the N protein of SARS-CoV-2 and
313 antibodies that block ACE-2 binding to the S protein of SARS-CoV-2 Wu-1 were measured
314 using the V-PLEX SARS-CoV-2 Panel 2 (Meso Scale Diagnostics, Maryland, USA) for IgG
315 and ACE-2 according to the manufacturer's instruction at the SciLifeLab Affinity Proteomics
316 Unit (Uppsala, Sweden). More details on the immunological methods are found in
317 Supplemental methods section.

318

319 ***In vitro* neutralization assays**

320 Assessment of the potency of serum to neutralize authentic SARS-CoV-2 *in vitro* was
321 performed under BSL-3 conditions as previously described²⁸ Pseudovirus neutralization was
322 performed as previously described²⁹ with modifications as described in Supplemental methods
323 section.

324

325 **Outcomes**

326 We assessed three outcomes: humoral immune responses to SARS-CoV-2 before and after a
327 vaccine dose, SARS-CoV-2 infection as determined by a SARS-CoV-2 RT-PCR-positive
328 clinical specimen, and SARS-CoV-2-associated mortality as defined by death occurring within

329 30 days after a SARS-CoV-2-infection. Outcomes were measured from 16 September 2021 to
330 31 August 2022 with follow-up of deaths until 30 September 2022.

331

332 **Data processing**

333 Data processing was carried out by R version 4.1.2 (2021-11-01) – “Bird Hippie”. The code is
334 available at [https://github.com/johanssonresearch/Correlate-of-vaccine-protection-against-](https://github.com/johanssonresearch/Correlate-of-vaccine-protection-against-fatal-COVID-19)
335 [fatal-COVID-19](https://github.com/johanssonresearch/Correlate-of-vaccine-protection-against-fatal-COVID-19)

336

337 **Covariates**

338 We adjusted analyses at all time points for previous SARS-CoV-2 infections verified by SARS-
339 CoV-2 PCR-positivity. We further adjusted the analyses for date of birth, gender, and nursing
340 home caregiver.

341

342 **Statistical analyses**

343 Vaccine coverage was calculated based on the vital population at the data for the first
344 administration of the 3rd and 4th mRNA vaccine dose, respectively. We used a cubic spline
345 model with 8 and 10 knots for vaccine dose 3 and 4, respectively, to capture and plot the non-
346 linear trend of S-directed antibody levels in blood over time. We used a generalized additive
347 model with cubic splines to test for difference in antibody levels after dose 3 between the
348 vaccines BNT162b2 and mRNA-1273 and for interaction between the vaccine and the decline
349 in AUC over time with adjustment for age and gender. We used observations of S-binding IgG
350 AUC in infection-naïve study subjects from day 20 to day 80 after dose 3 to approximate the
351 decline by logarithmic regression. SARS-CoV-2-associated 30-day mortality with and without
352 consideration of S-binding IgG antibody levels was analyzed by cumulative Kaplan-Meier
353 estimates and survival at day 30. We used a case-control design with two random controls

354 sampled the same day as each SARS-CoV-2 as described in the technical appendix 1. For
355 analyses of S-directed antibody level as a correlate of protection against SARS-CoV-2-
356 associated 30-day mortality, we classified the 528 Covid-19 cases into two groups: normal and
357 low antibody responders. Cases with an S-directed antibody AUC lower than given percentile
358 (2.5, 5, 7.5, 10, 12.5, 15, 17.5, 20) at day 60 post vaccine dose 3 were classified as low
359 responders and the other cases as normal responders. We used a Cox proportional hazard model
360 to estimate the risk of death within 30 days adjusting for *covid* (PCR-verified SARS-CoV-2
361 infection or no infection), *responder* (low or normal AUC-values), *age* (in years) and *gender*
362 (male or female assigned at birth). We used Graphpad Prism version 9.x for statistical analysis
363 of data in figures 2B and 3. We used non-parametric Mann-Whitney test, Wilcoxon matched-
364 pairs signed rank test for group wise comparisons, or non-parametric Kruskal-Wallis test as
365 appropriate. We used Dunn's multiple comparison test for post-hoc analyses.

366

367 **Role of funding sources**

368 The agencies funding these studies had no role in the study design or interpretation of data.

369

370 **Acknowledgements**

371 We would like to thank the Swedish Public Health Agency for their support of this study and
372 the Clinical Research Center at the University Hospital of Northern Sweden for assistance with
373 sampling. We thank the coordinating study nurses Maria Grimfelt and Ida-Lisa Persson, and
374 regional study nurses. We would also like to thank Maj Järner, Jenny Gardfjäll, Jasmin
375 Nazemroya and Andy Dernstedt for assistance with sample processing. Finally, we would like
376 to acknowledge all study subjects for their participation in this study, and the personnel at the
377 nursing homes for invaluable support.

378

379 **Funding**

380 This project was funded by grants from the Swedish Research Council (2020-06235 to MNEF,
381 2021-04665 to CA and 2020-05782 to JK), SciLifeLab reseach programs funded by Knut and
382 Alice Wallenberg (VC2021-0018 and VC2022-0008 to MNEF, VC2022-0028 to MNEF and
383 AJ and VC2021-0026 to JK), and Swedish Healthcare Regions (VISARENORR968921, RV-
384 970105 and RV-982630 to AJ). J.N. is a Wallenberg Center for Molecular Medicine Associated
385 Researcher.

386

387 **Conflict of interest**

388 The authors declare no conflict of interest.

389

390 **References**

- 391 1. Team C-F. Variation in the COVID-19 infection-fatality ratio by age, time, and
392 geography during the pre-vaccine era: a systematic analysis. *Lancet*
393 2022;399(10334):1469-1488. DOI: 10.1016/S0140-6736(21)02867-1.
- 394 2. Statens offentliga utredningar SR. Delbetänkande 1 – Äldreomsorgen under pandemin
395 SOU 2020:80. 2020;
396 ([https://coronakommissionen.com/wp-](https://coronakommissionen.com/wp-content/uploads/2020/12/sou_2020_80_aldreomsorgen-under-pandemin_webb.pdf)
397 [content/uploads/2020/12/sou_2020_80_aldreomsorgen-under-](https://coronakommissionen.com/wp-content/uploads/2020/12/sou_2020_80_aldreomsorgen-under-pandemin_webb.pdf)
398 [pandemin_webb.pdf](https://coronakommissionen.com/wp-content/uploads/2020/12/sou_2020_80_aldreomsorgen-under-pandemin_webb.pdf)).
- 399 3. Statens offentliga utredningar SR. Delbetänkande 1 – Äldreomsorgen under pandemin
400 SOU 2020:80 Summary in English. 2020
401 ([https://www.government.se/4af26a/contentassets/2b394e1186714875bf29991b45](https://www.government.se/4af26a/contentassets/2b394e1186714875bf29991b4552b374/summary-of-sou-2020_80-elderly-care-during-the-pandemic.pdf)
402 [52b374/summary-of-sou-2020_80-elderly-care-during-the-pandemic.pdf](https://www.government.se/4af26a/contentassets/2b394e1186714875bf29991b4552b374/summary-of-sou-2020_80-elderly-care-during-the-pandemic.pdf)).
- 403 4. Bergman J, Ballin M, Nordstrom A, Nordstrom P. Risk factors for COVID-19 diagnosis,
404 hospitalization, and subsequent all-cause mortality in Sweden: a nationwide study. *Eur*
405 *J Epidemiol* 2021;36(3):287-298. DOI: 10.1007/s10654-021-00732-w.
- 406 5. Ballin M, Bergman J, Kivipelto M, Nordstrom A, Nordstrom P. Excess Mortality After
407 COVID-19 in Swedish Long-Term Care Facilities. *J Am Med Dir Assoc* 2021;22(8):1574-
408 1580 e8. DOI: 10.1016/j.jamda.2021.06.010.
- 409 6. Folkhälsomyndigheten. The Public Health Agency of Sweden Press conference 1 April
410 2021. 2021 (<https://share.mediaflow.com/se/?SDFE9O7K3O>).
- 411 7. Anderson EJ, Roupael NG, Widge AT, et al. Safety and Immunogenicity of SARS-CoV-
412 2 mRNA-1273 Vaccine in Older Adults. *N Engl J Med* 2020;383(25):2427-2438. DOI:
413 10.1056/NEJMoa2028436.

- 414 8. Collier DA, Ferreira I, Kotagiri P, et al. Age-related immune response heterogeneity to
415 SARS-CoV-2 vaccine BNT162b2. *Nature* 2021;596(7872):417-422. DOI:
416 10.1038/s41586-021-03739-1.
- 417 9. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-
418 2 Vaccine. *N Engl J Med* 2021;384(5):403-416. DOI: 10.1056/NEJMoa2035389.
- 419 10. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA
420 Covid-19 Vaccine. *N Engl J Med* 2020;383(27):2603-2615. DOI:
421 10.1056/NEJMoa2034577.
- 422 11. Walsh EE, Frenck RW, Jr., Falsey AR, et al. Safety and Immunogenicity of Two RNA-
423 Based Covid-19 Vaccine Candidates. *N Engl J Med* 2020;383(25):2439-2450. DOI:
424 10.1056/NEJMoa2027906.
- 425 12. Tober-Lau P, Schwarz T, Vanshylla K, et al. Long-term immunogenicity of BNT162b2
426 vaccination in older people and younger health-care workers. *Lancet Respir Med*
427 2021;9(11):e104-e105. DOI: 10.1016/S2213-2600(21)00456-2.
- 428 13. Schwarz T, Tober-Lau P, Hillus D, et al. Delayed Antibody and T-Cell Response to
429 BNT162b2 Vaccination in the Elderly, Germany. *Emerg Infect Dis* 2021;27(8):2174-
430 2178. DOI: 10.3201/eid2708.211145.
- 431 14. Pajon R, Doria-Rose NA, Shen X, et al. SARS-CoV-2 Omicron Variant Neutralization after
432 mRNA-1273 Booster Vaccination. *N Engl J Med* 2022;386(11):1088-1091. DOI:
433 10.1056/NEJMc2119912.
- 434 15. Nordstrom P, Ballin M, Nordstrom A. Effectiveness of a fourth dose of mRNA COVID-
435 19 vaccine against all-cause mortality in long-term care facility residents and in the
436 oldest old: A nationwide, retrospective cohort study in Sweden. *Lancet Reg Health Eur*
437 2022;100466. DOI: 10.1016/j.lanepe.2022.100466.
- 438 16. Bystrom JW, Vikstrom L, Rosendal E, et al. Serological assessment of SARS-CoV-2
439 exposure in northern Sweden by the use of at-home sampling to meet geographical
440 challenges in rural regions. *medRxiv* 2022. DOI: 10.1101/2020.06.02.20120477.
- 441 17. Qu P, Faraone J, Evans JP, et al. Neutralization of the SARS-CoV-2 Omicron BA.4/5 and
442 BA.2.12.1 Subvariants. *N Engl J Med* 2022;386(26):2526-2528. DOI:
443 10.1056/NEJMc2206725.
- 444 18. Forsell MNE, Kvastad L, Sedimbi SK, Andersson J, Karlsson MCI. Regulation of Subunit-
445 Specific Germinal Center B Cell Responses to the HIV-1 Envelope Glycoproteins by
446 Antibody-Mediated Feedback. *Front Immunol* 2017;8:738. DOI:
447 10.3389/fimmu.2017.00738.
- 448 19. Zhang Y, Meyer-Hermann M, George LA, et al. Germinal center B cells govern their own
449 fate via antibody feedback. *J Exp Med* 2013;210(3):457-64. DOI:
450 10.1084/jem.20120150.
- 451 20. Tas JMJ, Koo JH, Lin YC, et al. Antibodies from primary humoral responses modulate
452 the recruitment of naive B cells during secondary responses. *Immunity*
453 2022;55(10):1856-1871 e6. DOI: 10.1016/j.immuni.2022.07.020.
- 454 21. Andrews N, Stowe J, Kirsebom F, et al. Covid-19 Vaccine Effectiveness against the
455 Omicron (B.1.1.529) Variant. *N Engl J Med* 2022;386(16):1532-1546. DOI:
456 10.1056/NEJMoa2119451.
- 457 22. Willett BJ, Grove J, MacLean OA, et al. Publisher Correction: SARS-CoV-2 Omicron is an
458 immune escape variant with an altered cell entry pathway. *Nat Microbiol*
459 2022;7(10):1709. DOI: 10.1038/s41564-022-01241-6.

- 460 23. Gilbert PB, Donis RO, Koup RA, Fong Y, Plotkin SA, Follmann D. A Covid-19 Milestone
461 Attained - A Correlate of Protection for Vaccines. *N Engl J Med* 2022;387(24):2203-
462 2206. DOI: 10.1056/NEJMp2211314.
- 463 24. Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the
464 mRNA-1273 COVID-19 vaccine efficacy clinical trial. *Science* 2022;375(6576):43-50.
465 DOI: 10.1126/science.abm3425.
- 466 25. Zhang A, Stacey HD, D'Agostino MR, Tugg Y, Marzok A, Miller MS. Beyond
467 neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection. *Nat*
468 *Rev Immunol* 2022:1-16. DOI: 10.1038/s41577-022-00813-1.
- 469 26. Havervall S, Marking U, Svensson J, et al. Anti-Spike Mucosal IgA Protection against
470 SARS-CoV-2 Omicron Infection. *N Engl J Med* 2022;387(14):1333-1336. DOI:
471 10.1056/NEJMc2209651.
- 472 27. Marking U, Bladh O, Havervall S, et al. 7-month duration of SARS-CoV-2 mucosal
473 immunoglobulin-A responses and protection. *Lancet Infect Dis* 2023. DOI:
474 10.1016/S1473-3099(22)00834-9.
- 475 28. Normark J, Vikstrom L, Gwon YD, et al. Heterologous ChAdOx1 nCoV-19 and mRNA-
476 1273 Vaccination. *N Engl J Med* 2021;385(11):1049-1051. DOI:
477 10.1056/NEJMc2110716.
- 478 29. Sheward DJ, Kim C, Fischbach J, et al. Evasion of neutralising antibodies by omicron
479 sublineage BA.2.75. *Lancet Infect Dis* 2022;22(10):1421-1422. DOI: 10.1016/S1473-
480 3099(22)00524-2.

481

482

483 **FIGURE LEGENDS**

484

485 **Figure 1.** Location of nursing homes, age and gender characteristics, and the progression of
486 PCR-verified SARS-CoV-2 infections in the study population of 3012 study subjects. Panel A
487 shows locations in Sweden of nursing homes with recruitment of study subjects in two
488 metropolitan areas (Stockholm and Malmö; blue color) and three less densely populated
489 regions (Västerbotten, Jämtland-Härjedalen and Örebro; red color). Panel B shows
490 proportions of the total population stratified per age-group of women (blue bars) and men (red
491 bars) An asterisk indicates that one 41-year-old study subject was included. Panel C shows
492 PCR-verified SARS-CoV-2 incidence among the study subjects over the entire pandemic.
493 Timing of vaccine doses, study start, blood sampling periods, dominating virus variant,

494 periods of vaccination, and blood sampling are indicated. For vaccination and sampling, a
495 gray-shaded interval represents that 80% of the population was completed.

496

497 **Figure 2. Dynamics and projection of S-directed IgG responses.** Panel A shows S-directed
498 IgG levels with respect to the 3rd dose mRNA-vaccination, as assessed by repeated capillary
499 blood sampling of previously uninfected (blue) or previously infected (red) nursing home
500 residents. Day 0 is the day of vaccination. Shading indicates 95% confidence intervals. Panel
501 B shows comparison of S-directed IgG in the nursing home population (blue) and community
502 living individuals up to the age of 65 (red) and those previously infected with SARS-CoV-2
503 covid-19 from both groups (black crosses). Median for each group is shown. Panel C shows S-
504 directed IgG levels before and after the 4th dose mRNA-vaccination of the nursing home
505 population. Each dot represents one study subject.


506


507 **Figure 3. Detailed effect of booster vaccination.**

508 Samples from nursing home residents (blue circles), community living older individuals (red
509 circles) or community living younger individuals (≤ 65 years, black circles) were assessed for
510 S-binding IgG (Panel A) or authentic neutralization against Wu-1 isolate of SARS-CoV-2
511 (Panel B). S-binding is shown as the area under the curve for each sample (AUC) and the
512 reciprocal serum dilution at which 50% neutralization was achieved (NT50%). Panel C shows
513 neutralization of SARS-Cov-2 S-pseudotyped virus by serum from nursing home residents on
514 day 0 (open circles) and 30 post (black circles) dose 4. Reciprocal serum dilution where 50%
515 neutralization of SARS-CoV-D614G, BA.2, BA.2.75 or BA.5 is shown (NT50%). Each dot
516 represents one individual.


517

518 **Figure 4. SARS-CoV-2-associated 30-day mortality.** Panel A shows cumulative 30-day
519 SARS-CoV-2-associated mortality among 528 previously infection naïve nursing home
520 residents that were vaccinated with three or four mRNA vaccine doses before the infection
521 (red). Control study subjects (blue) were sampled 2:1 adjusted to calendar time. Panel B
522 shows the SARS-CoV-2 related 30-day mortality with respect to S-binding IgG levels in the
523 nursing home population. The mortality is shown in relation to the percentile range of lowest
524 antibody levels among the 528 SARS-CoV-2 cases and refers to antibody levels at day 60
525 post vaccine dose 3.
526






A




B



- Nursing home residents (median age: 84)
- Community living > 65 years (median age: 82)
- Community living \leq 65 years (median age: 57)

C



- ◇ Previously Covid-19 infected individuals
- Covid-19 naïve individuals

